Sign in
Taking people in South KoreaNo phase

Tests combined diabetes drug strategies to lower blood sugar in type 2 diabetes

Tests combined drug and glucose monitor strategies in adults with type 2 diabetes.

Key facts

Who runs it
Kyu Chang Won
Where
Daegu and Seoul, South KoreaSee the 2 sites
Trial code
Registry title
A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH)
Status
Recruiting
People taking part
5,950 people, planned
Started
21 Nov 2024
Expected to end
30 Sept 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Dual-combination therapy
  • Triple-combination therapy
  • Dexcom G7, Pasta
Record updated
24 April 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes who still have raised HbA1c on diabetes tablets and who also have heart or blood vessel risk factors or diabetes complications.

Age
19 years and older
Sex
All sexes can join
Disease stage
Type 2 diabetes with HbA1c 7.0% (53 mmol/mol) or higher and under 10.0% (86 mmol/mol) on one, two or three diabetes tablets. Also needs heart disease, stroke, long diabetes (10 years or more), kidney, eye or nerve problems, or two or more heart risk factors.
Earlier treatment
Must already take diabetes tablets (one, two or three drugs, at a submaximal dose for three).
Biomarker or test result
HbA1c 7.0% (53 mmol/mol) or higher and under 10.0% (86 mmol/mol)

Main reasons for not taking part

  • Type 1 diabetes
  • Kidney function (eGFR) under 45 ml/min/1.73m²
  • Liver tests (AST or ALT) more than 3 times the upper normal limit
  • Heart failure with symptoms (NYHA Class III or IV)
  • Hospital stay for a heart or blood vessel event in the last 3 months

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • ≥19 years of age
  • Patient agreed to participate in the study and signed a written informed consent form
  • Type 2 diabetes (ADA criteria)
  • HbA1c≥7.0% and \<10.0% in patients receiving monotherapy, dual-combination therapy, or triple-combination therapy (when the submaximal dose was administered) with oral antidiabetic drugs (OADs)
  • Any of the following:
  • Patients who one or more of the following conditions
  • Coronary artery disease
  • Atherosclerotic ischemic stroke, transient ischemic attack, carotid artery disease, peripheral artery disease, abdominal aortic aneurysm
  • Prevalence of diabetes ≥10 years
  • Left ventricular hypertrophy
  • Albuminuria
  • Chronic kidney disease (eGFR\<60mL/min/1.73m²)
  • Diabetic Retinopathy
  • Diabetic neuropathy or B. Patients who have two or more of the following cardiovascular risk factors; (1) Family history of early-onset ASCVD (first-degree relatives with disease before age 55 for men and before age 65 for women) (2) Hypertension (on medication or with SBP≥140 mm Hg or DBP≥90 mm Hg) (3) Low HDL cholesterol concentration (\<40 mg/dL) (4) Current smoker (5) Obese (BMI≥25 kg/m²)

Who cannot take part

  • History of hospitalization for acute cardiovascular events within 3 months prior to the date of consent
  • Contraindications for each assigned drug, as applicable
  • Type 1 diabetes
  • Symptomatic heart failure (NYHA Class III or IV)
  • Currently in active treatment for malignancy
  • Estimated GFR\<45 ml/min/1.73m²
  • AST or ALT greater than 3 times the normal upper limit
  • Pregnant and nursing women
  • If the investigator determines that assignment to the standard glycemic control arm raises ethical concerns

Where in South Korea

  • Yeungnam University Medical CenterDaegu, South KoreaContact: Won, M.D., Ph.D.Not yet recruiting
  • Korea University Anam HospitalSeoul, South KoreaContact: Sin Gon Kim, M.D., Ph.D.Taking people

About the trial

What the trial wants to find out

Glycemic control is a mainstay of diabetes management to reduce the risk of microvascular complications and cardiovascular outcomes in people with type 2 diabetes (T2D). However, intensive control to near-normal glycated hemoglobin (HbA1c) yielded complex results in previous landmark trials. Potential risks of intensive glycemic control, such as hypoglycemia and weight gain, may partly contributed to the possible harms associated with this approach. Recent advances in diabetes management with development of newer antidiabetic drugs which minimize possible harms of intensive glycemic control as well as reduce cardiorenal risks enabled safer glycemic reduction. Thus, this randomized trial aims to evaluate the effects of near normalization of HbA1c with novel approaches on microvascular complications and cardiovascular outcomes in people with T2D.

The 2 groups in the trial

  • Standard treatment arm (HbA1c 7.0% target)Existing treatment, for comparison

    Metformin/DPP-4i-based or Metformin/SGLT2i-based dual-combination therapy. Treatment and Follow-up : Maximum 4 years

    Treatment: Dual-combination therapy

  • Intensive treatment arm (HbA1c 6.0% target): plus real-time CGMTreatment being tested

    Randomly assigned into 2 sub-groups Device: Dexcom G7 plus Kakaohealthcare Pasta. (Barozen Fit is also available.) Treatment and Follow-up : Maximum 4 years

    Treatment: Triple-combination therapy and Dexcom G7, Pasta

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Registry Based Randomized Controlled Trial of Multiple Combination Strategies of Intensive Glycemic Control to Reduce a Composite of Macrovascular and Microvascular Events in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH Study)
Plain-language title
Tests combined diabetes drug strategies to lower blood sugar in type 2 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
24 April 2025